STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #381 by analyst upside · 2026-09-16
QTTB
Q32 Bio Inc.
Healthcare · Market Cap $333M · P/E 3.5x
ANALYST PRICE TARGET
+267.1%
implied upside to consensus target
Current Price $11.17
Consensus Target $41.0
Bull Target $59.0
Bear Target $34.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
0
Sell
0
52-Week Low $1.69
52-Week High $23.57
YTD Return +224.7%
FUNDAMENTALS
Market Cap $333M
P/E Ratio (TTM) 3.5x
Forward P/E N/A
EPS (TTM) $3.22
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $54M
Profit Margin 62.9%
52-WEEK RANGE
52-Week Low $1.69
52-Week High $23.57
Current Price $11.17
Bear Target $34.0
Bull Target $59.0
● Now $11.17 ● Target $41.0
TRADING DATA
Avg Volume 1.2M
YTD Return +224.7%
Analyst Count 5
Consensus Buy
Upside to Target +267.1%
Last Updated 2026-09-16

ANALYST SUMMARY

Q32 Bio Inc. (QTTB) is currently trading at $11.17 with a Wall Street consensus price target of $41.0, implying potential upside of 267.1% over the next 12 months. 5 analysts currently cover QTTB, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $59.0, while the most cautious has a target of $34.0.

QTTB operates in the Healthcare sector with a market capitalisation of $333M. The stock is up 224.7% year-to-date and is currently trading near the lower end of its 52-week range of $1.69 – $23.57.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for QTTB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley ● Initiated
Overweight 2026-08-24 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-07-28 31% win rate (48 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-07-13 14% win rate (7 calls)
Wells Fargo ↑ Upgrade
Equal-Weight → Overweight 2026-07-13 Building track record
Mizuho ● Initiated
Outperform 2026-05-22 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2026-05-18 40% win rate (10 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-05-05 31% win rate (48 calls)
HC Wainwright & Co. ● Initiated
Buy 2026-02-25 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →